Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast to 2023 - United States

  • ID: 3774303
  • Drug Pipelines
  • Region: Global, United States
  • 60 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Astrazeneca, Inc.
  • Chidamide
  • Chipscreen Biosciences
  • Curis Inc.
  • Novartis Pharmaceuticals
  • MORE
“Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast to 2023 - US” Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) Breast Cancer from 2013-2023. According to the publisher, the forecasted patient population of ER+ breast cancer will increase at a CAGR of 2.03% from 2015 to 2023 and the worldwide ER+ breast cancer market is estimated to be 2.86 billion by 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Note: This report will be delivered to the client in 48 hours

Scope
- Report covers the disease overview, current treatment options, prescription drugs and emerging therapies.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2013-2023.
- It also provides Market size of Estrogen Receptor Positive (ER+) Breast Cancer for United States and forecasted Market size to 2023.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Astrazeneca, Inc.
  • Chidamide
  • Chipscreen Biosciences
  • Curis Inc.
  • Novartis Pharmaceuticals
  • MORE
Table of Contents

1 Report Introduction
2 Executive Summary
- Key Findings
3 ER+ Breast Cancer Market Overview at a Glance
- Worldwide Market Size of ER+ Breast Cancer in 2013
- Worldwide Market Size of ER+ Breast Cancer in 2023
4 Treatment Landscape
- Treatment Options by Stage
- Stage IA
- Stage IB
- Stage IC
- Stage IIA
- Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV
- Treatment Algorithm
- Treatment Follow-Up
5 Epidemiology and Patient Population
- Key Findings
- Overview
- Disease Classification
- Population and Forecast Methodology
- Total Incident Cases
- Diagnosed Drug Treated Population
- Percentage Diagnosed
- Percentage Drug Treated
6 Current Medical Practice and Therapies in Use
- Key Findings
- Overview of ER+ Breast Cancer
- Treatment Goals
- Currently Medical Practice
- Overview of ER+ Breast Cancer Drug Classification
- Prescription Drugs, Dosing & Route
7 Emerging Therapies
- Key Findings
- Unmet need
- Late Stage Pipeline Overview
- Expected Launch date of these therapies in United States
- Late Stage Pipeline Analysis
- Efficacy & Safety Results
8 United States Market Assessment
- Key Findings
- United States Market Forecast
- United States Market Size
- Market Driver and Constraints
- Factors Driving the Market for ER+ Breast Cancer
- Factors Constraining the Market for ER+ Breast Cancer
9 Consulting Services
10 Disclaimer
11 About us
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Sanofi-Aventis
- Astellas Pharma
- Pfizer Inc.
- Novartis Pharmaceuticals
- Astrazeneca, Inc.
- Curis Inc.
- Chidamide
- Chipscreen Biosciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll